We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-3.18%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$263M
AUM Growth
-$143M
Cap. Flow
-$77.6M
Cap. Flow %
-29.53%
Top 10 Hldgs %
50.47%
Holding
61
New
21
Increased
10
Reduced
9
Closed
20

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$22.6M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$12.5M
3
BMY icon
Bristol-Myers Squibb
BMY
+$11.9M
4
MRNA icon
Moderna
MRNA
+$10.6M
5
PASG icon
Passage Bio
PASG
+$9.43M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$20.6M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$18.6M
3
APLS
Apellis Pharmaceuticals
APLS
+$18M
4
BLUE
bluebird bio
BLUE
+$17.9M
5
XLRN
Acceleron Pharma
XLRN
+$14.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
1
AbbVie
ABBV
$460B
$20.2M 7.7%
+265,600
New +$22.6M
SRPT icon
2
Sarepta Therapeutics
SRPT
$1.7B
$18.3M 6.97%
187,350
-38,652
-17% -$4.42M
MYOK
3
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$14.1M 5.35%
300,000
+68,991
+30% +$4.42M
MRNA icon
4
Moderna
MRNA
$22.2B
$13.8M 5.24%
+460,000
New +$10.6M
ASND icon
5
Ascendis Pharma A/S
ASND
$16.8B
$13.5M 5.14%
120,000
-59,898
-33% -$7.78M
RETA
6
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$11.9M 4.52%
82,292
+26,592
+48% +$5.13M
BMY icon
7
Bristol-Myers Squibb
BMY
$129B
$10.8M 4.12%
+194,500
New +$11.9M
ZYME icon
8
Zymeworks
ZYME
$1.71B
$10.8M 4.11%
304,417
-84,736
-22% -$3.47M
IGMS
9
DELISTED
IGM Biosciences
IGMS
$9.76M 3.71%
173,865
+59,454
+52% +$2.61M
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
$9.5M 3.61%
+185,933
New +$12.5M
PASG icon
11
Passage Bio
PASG
$15.6M
$8.96M 3.41%
+30,167
New +$9.43M
VRTX icon
12
Vertex Pharmaceuticals
VRTX
$123B
$7.91M 3.01%
+33,237
New +$7.62M
BLU
13
DELISTED
BELLUS Health Inc.
BLU
$7.74M 2.94%
775,377
+350,759
+83% +$3.13M
IOVA icon
14
Iovance Biotherapeutics
IOVA
$2.26B
$7.4M 2.82%
247,248
+26,705
+12% +$708K
FULC icon
15
Fulcrum Therapeutics
FULC
$251M
$6.36M 2.42%
532,520
+408,885
+331% +$6.54M
ETNB
16
DELISTED
89bio
ETNB
$6.24M 2.37%
247,000
+160,409
+185% +$4.69M
MTEM
17
DELISTED
Molecular Templates, Inc.
MTEM
$5.83M 2.22%
29,255
+6,595
+29% +$1.44M
VSTM icon
18
Verastem
VSTM
$561M
$5.53M 2.1%
+193,799
New +$4.86M
KRTX
19
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$5.01M 1.91%
69,658
+30,011
+76% +$2.57M
BMY.RT
20
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$4.85M 1.84%
1,275,500
-2,047,316
-62% -$6.74M
TXG icon
21
10x Genomics
TXG
$5.8B
$4.54M 1.73%
+72,831
New +$5.68M
CRSP icon
22
CRISPR Therapeutics
CRSP
$4.67B
$4.47M 1.7%
+105,512
New +$5.45M
BPMC
23
DELISTED
Blueprint Medicines
BPMC
$4.39M 1.67%
+75,000
New +$4.83M
ALNY icon
24
Alnylam Pharmaceuticals
ALNY
$37.8B
$4.32M 1.64%
+39,644
New +$4.58M
FATE icon
25
Fate Therapeutics
FATE
$283M
$4.29M 1.63%
+193,144
New +$4.88M
1
2 3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2020 Portfolio in Review

As of Q1 2020, Logos Global Management held 61 positions worth $263M, down 35% from $406M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Logos Global Management withdrew a net $77.6M in Q1 2020, closing 20 positions and reducing 9 holdings. Its most notable exit was Amarin Corp, an estimated $20.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 82% a quarter earlier.

Against the trend, Logos Global Management opened a new position in AbbVie worth $20.2M.

  • Logos Global Management's largest Q1 2020 buy was AbbVie: 265,600 shares worth $20.2M.
  • Logos Global Management added most to Fulcrum Therapeutics in Q1 2020, an estimated $6.54M increase.
  • Logos Global Management's biggest Q1 2020 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $18.6M.
  • Logos Global Management fully exited Amarin Corp in Q1 2020, selling an estimated $20.6M.
  • Logos Global Management's ten largest holdings make up 50% of its $263M portfolio in Q1 2020.
  • Logos Global Management opened 21 new positions and closed 20 in Q1 2020.
  • Logos Global Management's portfolio value fell 35% quarter-over-quarter to $263M.

Based on Logos Global Management's 13F filing for Q1 2020, filed 15 May 2020.